A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance
Listen to expert perspectives on selecting optimal therapy for patients with CLL, with a focus on how BTK inhibitor resistance mutations are assessed and how they affect therapy choice.
Decera Clinical Education Oncology Podcast · Matthew S. Davids MD MMSc, Lindsey Roeker MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, listen to Matthew S. Davids, MD, MMSc, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including:
- Contemporary treatment paradigms for patients with CLL
- Safety and efficacy of current regimens
- Molecular testing, including when and how to test for BTK inhibitor resistance
- Considering BTK inhibitor resistance when sequencing therapy
Program faculty:
Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts
Lindsey Roeker, MD
Assistant Attending
CLL Program Director
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Resources:
To review a CME-certified text activity and download slides associated with this podcast discussion, please visit the program page.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.